{
    "clinical_study": {
        "@rank": "115823", 
        "arm_group": [
            {
                "arm_group_label": "AT13387 and abiraterone", 
                "arm_group_type": "Experimental", 
                "description": "Part A: AT13387 IV with abiraterone 1000 mg QD and prednisone or prednisolone 5 mg BID"
            }, 
            {
                "arm_group_label": "AT13387 alone or in combination with abiraterone acetate", 
                "arm_group_type": "Experimental", 
                "description": "Part B: AT13387 alone or AT13387 with abiraterone acetate 1000 mg PO"
            }
        ], 
        "brief_summary": {
            "textblock": "A 2-part, Phase 1-2, open-label, parallel group, randomized study in patients with\n      Castration-Resistant Prostate Cancer (CRPC) who are no longer responding to treatment with\n      abiraterone and steroids. In Part A (Phase 1), patients will continue to receive the same\n      doses of abiraterone and steroids they were receiving prior to study entry and will be\n      randomized to receive 1 of 2 different treatment regimens of AT13387 in combination with\n      abiraterone. Once the best regimen is established in Part A, based on safety and antitumor\n      activity, patients will be randomized to the selected treatment regimen and dose of AT13387\n      in combination with abiraterone or AT13387 alone in Part B (Phase 2)."
        }, 
        "brief_title": "A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion:\n\n          1. Must have prostate cancer\n\n          2. Have received prior castration by orchiectomy and/or hormone therapy\n\n          3. Males >18 years of age\n\n          4. Normal activity level for self care\n\n          5. Have been receiving abiraterone therapy with a steroid for \u22651 month\n\n          6. Have disease progression on abiraterone as defined by either PSA progression,\n             radiographic or bone progression\n\n          7. Have adequate bone marrow, liver and kidney function\n\n          8. Must be willing to provide pre-existing tumor samples, if this material exists. If\n             pre-existing samples are not available, a sample must be obtained during screening\n\n          9. Must be willing and able to provide written informed consent and comply with the\n             protocol and study procedures\n\n        Exclusion:\n\n          1. Prior anti-cancer treatment with any Heat Shock Protein 90 (HSP90) inhibitor or\n             histone deacetylase (HDAC) inhibitor compound\n\n          2. Have received chemotherapy within 4 weeks prior to receiving study drug\n\n          3. Prior prostate surgery or radiotherapy within 4 weeks from the first dose of study\n             drug\n\n          4. Hypersensitivity to AT13387 or other components of the drug product\n\n          5. Treatment with any investigational drug within 4 weeks prior to the first dose of\n             study drug\n\n          6. Severe systemic diseases or active uncontrolled infections\n\n          7. Presence of a life-threatening illness, medical condition, organ system dysfunction,\n             or other factors\n\n          8. Abnormal heart function\n\n          9. Other cancer except for adequately treated basal cell or squamous cell carcinoma of\n             the skin, or superficial bladder cancer, or other cancer from which the subject has\n             been disease-free for at least 3 years;\n\n         10. No known brain or CNS involvement\n\n         11. Unable to receive corticosteroids or history of pituitary or adrenal dysfunction\n\n         12. Known history of human immunodeficiency virus (HIV) or seropositive test for\n             hepatitis C virus or hepatitis B virus"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "164", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01685268", 
            "org_study_id": "AT13387-04"
        }, 
        "intervention": [
            {
                "arm_group_label": "AT13387 and abiraterone", 
                "description": "Parallel", 
                "intervention_name": "AT13387 and abiraterone", 
                "intervention_type": "Drug", 
                "other_name": "AT13387 and Zytiga"
            }, 
            {
                "arm_group_label": "AT13387 alone or in combination with abiraterone acetate", 
                "description": "Parallel", 
                "intervention_name": "AT13387 alone", 
                "intervention_type": "Drug", 
                "other_name": "AT13387"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Prostate Cancer", 
        "lastchanged_date": "May 8, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90024"
                    }, 
                    "name": "University of California, Los Angeles Institute of Urologic Oncology"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305"
                    }, 
                    "name": "Stanford Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Lauderdale", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33308"
                    }, 
                    "name": "Holy Cross Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Myers", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33916"
                    }, 
                    "name": "Florida Cancer Specialists-Fort Myers"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lakeland", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33805"
                    }, 
                    "name": "Lakeland Regional Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Springfield", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "62702"
                    }, 
                    "name": "Southern Illinois University School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21201"
                    }, 
                    "name": "University of Maryland, Greenebaum Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bethesda", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20817"
                    }, 
                    "name": "Center for Cancer & Blood Disorders"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington University School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Omaha", 
                        "country": "United States", 
                        "state": "Nebraska", 
                        "zip": "68198"
                    }, 
                    "name": "University of Nebraska Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Las Vegas", 
                        "country": "United States", 
                        "state": "Nevada", 
                        "zip": "89169"
                    }, 
                    "name": "Comprehensive Cancer Centers of Nevada"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Buffalo", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14263"
                    }, 
                    "name": "Roswell Park Cancer Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lake Success", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "11042"
                    }, 
                    "name": "Clinical Research Alliance, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Columbia University Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Syracuse", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "13210"
                    }, 
                    "name": "SUNY Upstate Medical University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44195"
                    }, 
                    "name": "Cleveland Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15232"
                    }, 
                    "name": "University of Pittsburgh Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38120"
                    }, 
                    "name": "The West Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tacoma", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98405"
                    }, 
                    "name": "Northwest Medical Specialists, PLLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H2L 4MI"
                    }, 
                    "name": "Centre hospitalier de l'Universite de Montreal (CHUM)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28050"
                    }, 
                    "name": "Centro Integral Oncologico Clara Campal"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brighton", 
                        "country": "United Kingdom", 
                        "zip": "BN2 5BE"
                    }, 
                    "name": "Brighton & Sussex University Hospitals NHS Trust"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cambridge", 
                        "country": "United Kingdom", 
                        "zip": "CB2 0QQ"
                    }, 
                    "name": "Cambridge University Hospitals NHS Foundation Trust"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cardiff", 
                        "country": "United Kingdom", 
                        "zip": "CF14 2TL"
                    }, 
                    "name": "Velindre Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guildford", 
                        "country": "United Kingdom", 
                        "zip": "GU2 7XP"
                    }, 
                    "name": "University of Surrey"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "W6 8RF"
                    }, 
                    "name": "Charing Cross Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Royal Marsden Foundation Trust Instute of Cancer Researrch"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom", 
                        "zip": "M20 4BX"
                    }, 
                    "name": "The Christie Hospital NHS Trust"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nottingham", 
                        "country": "United Kingdom", 
                        "zip": "NG5 1PB"
                    }, 
                    "name": "Nottingham University Hospitals"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Southampton", 
                        "country": "United Kingdom", 
                        "zip": "S016 6YD"
                    }, 
                    "name": "University Hospital Southampton"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wirral", 
                        "country": "United Kingdom", 
                        "zip": "CH63 4JY"
                    }, 
                    "name": "Clatterbridge Cancer Centre NHS Foundation Trust"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone", 
        "overall_official": {
            "affiliation": "Royal Marsden Foundation Trust Institute of Cancer Research", 
            "last_name": "Johann De Bono, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Number of patients with adverse events\nChange in prostate specific antigen measurement and circulating tumor cell count every 4 weeks\nChange in tumor measurements by RECIST 1.1 every 12 weeks", 
                "measure": "Part A: Safety and tolerability of the combination of AT13387 and abiraterone and to select the most promising treatment regimen in CRPC patients who are no longer responding to treatment with abiraterone alone.", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Change in prostate specific antigen measurement and circulating tumor cell count every 4 weeks\nChange in tumor measurements by RECIST 1.1 every 12 weeks", 
                "measure": "Part B: Compare the antitumor activity (response rate per the Prostate Cancer Working Group 2 [PCWG2]) between single-agent AT13387 and combination of AT13387 plus abiraterone in patients who are no longer responding to treatment with abiraterone alone.", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01685268"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Area under the plasma concentration versus time curve (AUC) of AT13387 and abiraterone alone and in combination by Week 4\nMaximum concentration (Cmax) of AT13387 and abiraterone alone and in combination by Week 4", 
                "measure": "Pharmacokinetics of combination treatment of AT13387 and abiraterone.", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "CTC enumeration and characterization every 4 weeks.", 
                "measure": "Pharmacodynamics of combination treatment of AT13387 and abiraterone.", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "Assessment of progression free survival as measured by weeks", 
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "Overall survival as measured in weeks", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }
        ], 
        "source": "Astex Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astex Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}